Merck Raises Revenue Outlook, Cuts Profit Guidance After Terns Deal

Merck raised its 2026 revenue forecast to $66.3B-$67.3B following the Terns deal and strong Keytruda sales, but cut its profit guidance to $2.66-$2.76 EPS due to charges from the acquisition.

4 Aug, 10:35 — 4 Aug, 17:42

Post Share

Why this matters

Merck is a major pharmaceutical company, and its financial performance and strategic acquisitions have significant implications for investors and the broader healthcare market. Changes in revenue and profit guidance, especially when tied to M&A activity, signal the company's future direction and financial health.

Key entitiesMerck Terns Pharmaceuticals Keytruda

The Story

What 3 sources agree on, dispute, and miss

What sources agree on

Merck raised its revenue outlook for 2026
Merck cut its profit guidance for 2026
The profit guidance cut is linked to the acquisition of Terns Pharmaceuticals

Key claims1 agreed · 3 unverified

Merck projects 2026 EPS of $2.66-$2.76

unverified·seeking-alpha

Merck raises 2026 revenue view to $66.3B-$67.3B

unverified·seeking-alpha

Merck's second-quarter results were better-than-expected due to Keytruda strength

unverified·Yahoo

✓

Merck's profit guidance cut is due to a charge tied to its acquisition of Terns Pharmaceuticals

agreed·cnbcseeking-alpha

Coverage gaps

Specific 2026 EPS projection of $2.66-$2.76 and revenue view of $66.3B-$67.3B

Reportedseeking-alpha

MissingYahoocnbc

Merck's better-than-expected second-quarter results driven by Keytruda strength

ReportedYahoo

Missingseeking-alphacnbc

The Story

Analyzing sources…

Source Diversity

Moderate (37/100)

3 sources25/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left2

Left (2)

Yahoocnbc

Center

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 1 region4/34

US3

ℹAll sources from US region

Sources

Showing 2 of 3 sources

YahooMostly Factual6d ago

Merck posts better-than-expected second-quarter results on Keytruda strength

Read full article →

seeking-alphaMixed6d ago

Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal

Read full article →

Coverage Timeline

First report: cnbc · 4 Aug, 10:34|Full coverage: 3 · 7h|Window: 7h

Left-leaningCenterRight-leaning

cnbc4 Aug, 10:34First to report

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Yahoo4 Aug, 10:35

Merck posts better-than-expected second-quarter results on Keytruda strength

7h later

seeking-alpha4 Aug, 17:42Latest update

Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal

Story evolution

Initial Q2 Results and Guidance Update2026-08-04 morning

Merck released its second-quarter results, which were better than expected, and simultaneously updated its 2026 revenue and profit guidance.

Detailed Financial Projections2026-08-04 afternoon

Further details emerged regarding the specific EPS and revenue projections for 2026.

PERSPECTA

PERSPECTA

Merck Raises Revenue Outlook, Cuts Profit Guidance After Terns Deal

Why this matters

The Story

What sources agree on

Key claims1 agreed · 3 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Sources

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal

Coverage Timeline

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal

Story evolution

Related Stories

Mindanao Business Leaders Gather for 35th MinBizCon

New Clark City Lacks Capacity for AI, Hyperscale Data Centers

Mimaropa Region Sees Slowdown in July Inflation

Dutch Home Prices Continue to Rise in Most Municipalities

PERSPECTA

Why this matters

Story evolution

The Story

What sources agree on

Key claims1 agreed · 3 unverified

Coverage gaps

Coverage matrix